-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is only for medical professionals to read and reference.
From 18:00-19:30 on May 11, the China Hepatitis Cloud Forum is waiting for you! At present, the situation of liver cancer in my country is still severe.
According to the latest data for 2020, more than 410,000 people in China have new cases of liver cancer, and more than 390,000 people have died of liver cancer.
The number of deaths is directly approaching the number of new cases.
In the field of hepatocellular carcinoma (HCC), which accounts for the largest proportion, the overall survival of patients is not optimistic.
The median survival time of HCC patients in China is less than 2 years, and the 5-year recurrence rate after HCC is as high as 60% to 70%.
Persistent hepatitis B virus (HBV) infection is not only an important risk factor for the occurrence, development and recurrence of HCC, but also a risk factor for death in HCC patients.
In addition, HBV reactivation is another challenge that needs to be faced in the treatment of HBV-related HCC, which urgently needs clinical attention.
Have you ever encountered such a situation in the clinic: It is clear that the baseline HBV DNA or hepatitis B surface antigen is negative before treatment, and the virus reactivation suddenly occurs after immunosuppressant treatment or chemotherapy, which seriously affects the survival of the patient.
So, we can't help asking, even if the patient's preoperative HBV level is low, do they need antiviral therapy? Is antiviral therapy really necessary for patients undergoing HBV-related HCC surgery? With these clinical questions, let us walk into the new issue of the China Hepatitis Cloud Forum, and listen to the opinions of the medical and surgical experts? Lock on May 11 (Tuesday) 18:00-19:30, discuss HBV-related HCC antiviral treatment together, express your thoughts, and show your attitude.
We look forward to your participation.
Scan the QR code to watch the spoilers of the live broadcast.
High-energy strikes 1HBV-related HCC patients.
Is antiviral treatment not essential? In my country, the proportion of HBV-related HCC patients is relatively high.According to the survey report, among the 22,201 patients with primary liver cancer, as many as 83.
77% have a history of HBV infection.
Compared with HCC caused by other reasons, the postoperative prognosis of HBV-related HCC patients is worse.
At the same time, data from multiple studies have shown that high viral load or HBV reactivation is associated with a high risk of HCC recurrence, which also suggests the potential role of antiviral therapy in preventing liver cancer recurrence.
However, in clinical practice, the current status of HBV-related HCC patients receiving antiviral therapy is not optimistic.
A number of retrospective studies have shown that more than 80% of patients have not received antiviral treatment before surgery.
At present, hepatectomy is still the most commonly used treatment for HCC, but according to related literature, the recurrence rate after 5 years is more than 70%.
In addition, there are multiple treatment methods such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy.
For HBV-related HCC patients, antiviral therapy can not only inhibit virus replication and reactivation, improve liver function, and increase surgical safety It can also reduce the reactivation of HBV caused by anti-tumor therapy and reduce the incidence of end-stage liver disease events.
At the same time, active antiviral therapy can also significantly enhance the tolerance of HCC patients to anti-tumor recurrence therapy, thereby improving overall survival.
2How to choose a specific antiviral program for HBV-related HCC? Antiviral therapy can benefit HBV-related HCC patients and needs to run through the entire treatment process of patients.
However, how to choose antiviral drugs requires comprehensive consideration from four aspects: virological inhibition rate, ALT recovery rate, drug resistance, and drug safety.
Relevant data show that the overall survival rate of HBV-related HCC patients who obtain sustained virological suppression is higher, and the earlier the HBV DNA is undetectable, the better the prognosis after liver cancer surgery.
For patients with chronic hepatitis B (CHB), resistance to antiviral drugs will lead to a higher risk of HCC, and ultimately reduce the survival rate of patients.
In addition, current HCC treatment drugs, such as chemotherapy drugs, immunosuppressive agents, etc.
, may have varying degrees of risk of kidney damage.Therefore, it is very important to choose strong, highly resistant, and safe antiviral drugs.
The current guidelines recommend the use of first-line antiviral drugs for chronic hepatitis B, such as propofol tenofovir (TAF).
Five-year data shows that CHB patients receiving TAF treatment can maintain a high viral suppression rate and alanine aminotransferase (ALT) normalization rate, and TAF has good renal safety.
During the five-year treatment period, the renal size estimated by the Cockcroft-Gault formula in CHB patients Sphere filtration rate (eGFRCG) only slightly decreased; the 5th year of resistance monitoring also did not observe the occurrence of genotype resistance.
Anti-Virus Workshop Wonderful Review of China Hepatitis Cloud Forum-Optimization of Diagnosis and Treatment of Chronic Hepatitis B.
View more exciting live broadcasts in the past for more latest literature, guidelines and cutting-edge information in infectious diseases, hepatitis and AIDS.
Welcome to pay attention to "Ji "Wisdom Doctor"-Statement: This content is only for Chinese medical and health professionals, and aims to provide scientific information to and only to medical and health professionals for personal learning and reference purposes.
If you are not a medical and health professional, please do not participate or spread it.
-End-
From 18:00-19:30 on May 11, the China Hepatitis Cloud Forum is waiting for you! At present, the situation of liver cancer in my country is still severe.
According to the latest data for 2020, more than 410,000 people in China have new cases of liver cancer, and more than 390,000 people have died of liver cancer.
The number of deaths is directly approaching the number of new cases.
In the field of hepatocellular carcinoma (HCC), which accounts for the largest proportion, the overall survival of patients is not optimistic.
The median survival time of HCC patients in China is less than 2 years, and the 5-year recurrence rate after HCC is as high as 60% to 70%.
Persistent hepatitis B virus (HBV) infection is not only an important risk factor for the occurrence, development and recurrence of HCC, but also a risk factor for death in HCC patients.
In addition, HBV reactivation is another challenge that needs to be faced in the treatment of HBV-related HCC, which urgently needs clinical attention.
Have you ever encountered such a situation in the clinic: It is clear that the baseline HBV DNA or hepatitis B surface antigen is negative before treatment, and the virus reactivation suddenly occurs after immunosuppressant treatment or chemotherapy, which seriously affects the survival of the patient.
So, we can't help asking, even if the patient's preoperative HBV level is low, do they need antiviral therapy? Is antiviral therapy really necessary for patients undergoing HBV-related HCC surgery? With these clinical questions, let us walk into the new issue of the China Hepatitis Cloud Forum, and listen to the opinions of the medical and surgical experts? Lock on May 11 (Tuesday) 18:00-19:30, discuss HBV-related HCC antiviral treatment together, express your thoughts, and show your attitude.
We look forward to your participation.
Scan the QR code to watch the spoilers of the live broadcast.
High-energy strikes 1HBV-related HCC patients.
Is antiviral treatment not essential? In my country, the proportion of HBV-related HCC patients is relatively high.According to the survey report, among the 22,201 patients with primary liver cancer, as many as 83.
77% have a history of HBV infection.
Compared with HCC caused by other reasons, the postoperative prognosis of HBV-related HCC patients is worse.
At the same time, data from multiple studies have shown that high viral load or HBV reactivation is associated with a high risk of HCC recurrence, which also suggests the potential role of antiviral therapy in preventing liver cancer recurrence.
However, in clinical practice, the current status of HBV-related HCC patients receiving antiviral therapy is not optimistic.
A number of retrospective studies have shown that more than 80% of patients have not received antiviral treatment before surgery.
At present, hepatectomy is still the most commonly used treatment for HCC, but according to related literature, the recurrence rate after 5 years is more than 70%.
In addition, there are multiple treatment methods such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy.
For HBV-related HCC patients, antiviral therapy can not only inhibit virus replication and reactivation, improve liver function, and increase surgical safety It can also reduce the reactivation of HBV caused by anti-tumor therapy and reduce the incidence of end-stage liver disease events.
At the same time, active antiviral therapy can also significantly enhance the tolerance of HCC patients to anti-tumor recurrence therapy, thereby improving overall survival.
2How to choose a specific antiviral program for HBV-related HCC? Antiviral therapy can benefit HBV-related HCC patients and needs to run through the entire treatment process of patients.
However, how to choose antiviral drugs requires comprehensive consideration from four aspects: virological inhibition rate, ALT recovery rate, drug resistance, and drug safety.
Relevant data show that the overall survival rate of HBV-related HCC patients who obtain sustained virological suppression is higher, and the earlier the HBV DNA is undetectable, the better the prognosis after liver cancer surgery.
For patients with chronic hepatitis B (CHB), resistance to antiviral drugs will lead to a higher risk of HCC, and ultimately reduce the survival rate of patients.
In addition, current HCC treatment drugs, such as chemotherapy drugs, immunosuppressive agents, etc.
, may have varying degrees of risk of kidney damage.Therefore, it is very important to choose strong, highly resistant, and safe antiviral drugs.
The current guidelines recommend the use of first-line antiviral drugs for chronic hepatitis B, such as propofol tenofovir (TAF).
Five-year data shows that CHB patients receiving TAF treatment can maintain a high viral suppression rate and alanine aminotransferase (ALT) normalization rate, and TAF has good renal safety.
During the five-year treatment period, the renal size estimated by the Cockcroft-Gault formula in CHB patients Sphere filtration rate (eGFRCG) only slightly decreased; the 5th year of resistance monitoring also did not observe the occurrence of genotype resistance.
Anti-Virus Workshop Wonderful Review of China Hepatitis Cloud Forum-Optimization of Diagnosis and Treatment of Chronic Hepatitis B.
View more exciting live broadcasts in the past for more latest literature, guidelines and cutting-edge information in infectious diseases, hepatitis and AIDS.
Welcome to pay attention to "Ji "Wisdom Doctor"-Statement: This content is only for Chinese medical and health professionals, and aims to provide scientific information to and only to medical and health professionals for personal learning and reference purposes.
If you are not a medical and health professional, please do not participate or spread it.
-End-